ArticleClinical oral investigations2023
RFC3 serves as a novel prognostic biomarker and target for head and neck squamous cell carcinoma.
Article in Clinical oral investigations, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Effects of Probiotics on Inflammatory Biomarkers and Its Associations With Cardiac Autonomic Function in Women With Arterial Hypertension: A Secondary Analysis of a Randomized Clinical Trial.Probiotics and antimicrobial proteins · 2025Trial
- Royal Jelly Enhances the Sensitivity of Oral Squamous Cancer Cells to Paclitaxel, Suppressing Proliferation, Migration, and Glycolysis.Cell biochemistry and biophysics · 2025Article
- Multiple roles of replication factor C family in pan‑cancer (Review).Oncology reports · 2025Review
- A comparison of hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: a bioinformatics analysis.Translational cancer research · 2025Article
- Application of Modified ITBCC Criteria of Tumor Budding in Oral Squamous Cell Carcinoma and its Correlation with Clinicopathological Parameters and Overall Survival.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Identification of Prognostic Biomarkers in Gene Expression Profile of Neuroblastoma Via Machine Learning.Pediatric discovery · 2025Article
- Prognostic significance and pathogenesis of RFC3 gene expression in diffuse large B-cell lymphoma.PeerJ · 2025Article
- Increased SEC14L2 expression is associated with clinicopathological features and worse prognosis in oral squamous cell carcinoma.Odontology · 2024Article
- Article
- Alteration in PNMA1 expression is associated with poor prognosis and tumor immune infiltration in head and neck squamous cell carcinoma.Journal of oral biology and craniofacial researchArticle
- SND1, a novel m6A RNA regulator: Its high expression correlates with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.Journal of oral biology and craniofacial researchArticle
- Gingival acquired lymphangiectasia as a long-term effect of post-oncology intervention: A 20-year institutional audit.Journal of oral and maxillofacial pathology : JOMFPArticle
- Overexpression of insulin-like growth factor-2 mRNA-binding protein 1 is associated with periodontal disease.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHead and neck squamous cell carcinoma (HNSCC) is a prevalent cancer that originates from the squamous cells. The role of the replication factor C subunit 3 (RFC3) in HNSCC progression remains elusive. The aim of this study was to uncover RFC3 significance in HNSCC.
methodsThe Cancer Genome Atlas (TCGA-HNSCC) dataset was initially used to assess RFC3 expression and its association with HNSCC clinical features. Subsequently, quantitative reverse transcription PCR (RT-qPCR) confirmed RFC3 mRNA expression in oral squamous cell carcinoma (OSCC), a primary HNSCC type. Survival rates were evaluated using the Kaplan-Meier plot, while the Tumor Immune Estimation Resource (TIMER) database probed RFC3-immune cell interaction. Additionally, in silico tools were used to examine the RFC3 protein network and engagement in HNSCC pathways.
resultsRFC3 expression is significantly upregulated in HNSCC, including OSCC. Upregulated RFC3 expression was significantly correlated with the clinicopathological features of HNSCC, including tumor stage, grade, metastasis, and patient survival. RFC3 is also associated with immune cell infiltration. Functional analysis has highlighted its involvement in DNA replication, mismatch repair, and cell cycle pathways. Interestingly, RFC3 high expression is linked to well-known oncogenic signaling pathways, such as MYC/MYCN, HIPPO, and mTOR.
conclusionsIn conclusion, RFC3 can be considered a novel prognostic biomarker for HNSCC, and further studies on its functional mechanisms may help to use RFC3 as a therapeutic target for HNSCC. CLINICAL RELEVANCE: The clinical relevance of this study lies in identifying RFC3 as a novel biomarker and prognostic indicator for HNSCC, offering insights that could impact future clinical approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.